- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06376916
Sammenligning av magnesium 2g versus 4g versus placebo i forekomsten av behandling av AFF RVR (ATRIUM)
Atriell takykardi-reduksjon med intravenøs bruk av magnesium (ATRIUM) Studie: Sammenligning av magnesium 2g versus 4g versus placebo i forekomsten av behandling av AFF RVR
The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Intravenous magnesium has become a commonly utilized agent in the treatment of cardiac arrhythmias as an adjunct therapy to rate and rhythm control medications, such as its use in atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR). Though its benefit in the treatment of AFF RVR has been well documented, a consensus on the optimal dosing of magnesium has yet to be achieved. Only one randomized, controlled, double-blinded study has investigated the optimal dosing of magnesium.
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Marc McDowell, PharmD
- Telefonnummer: (708) 684-1078
- E-post: marc.mcdowell@aah.org
Studiesteder
-
-
Illinois
-
Oak Lawn, Illinois, Forente stater, 60453
- Rekruttering
- Advocate Christ Medical Center Emergency Department (ACMC ED)
-
Ta kontakt med:
- Marc McDowell, PharmD
- Telefonnummer: 708-684-6230
- E-post: marc.mcdowell@aah.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age > 18 years or older
- Able to provide informed consent
- Primary diagnosis AFF RVR greater than or equal to 120 bpm
- Diltiazem as rate control agent
- English speaking
Exclusion Criteria:
- Hemodynamically unstable patients (SBP <90, MAP <65)
- Impaired consciousness
- End stage renal disease on hemodialysis or peritoneal dialysis
- Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
- Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
- Rhythms other than AF, such as sick sinus syndrome or wide-complex ventricular response
- Acute myocardial infarction
- Pregnancy defined as a positive urine HCG (human chorionic gonadotropin)
- Contraindications to magnesium sulfate (including myasthenia gravis)
- Allergy or sensitivity to any study drugs
- Previously enrolled in this trial during a different patient encounter
- Withdrew from study
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Experimental Arm One, Magnesium Sulfate 2g
Study drug (Magnesium Sulfate 2 gram/50ml 0.9% NaCl) |
Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
Andre navn:
|
|
Eksperimentell: Experimental Arm Two, Magnesium Sulfate 4g
Magnesium Sulfate 4g/50ml 0.9% NaCl |
Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
Andre navn:
|
|
Placebo komparator: Control Arm, normal saline
50ml 0.9% NaCl |
The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Ventricular rate control
Tidsramme: Within the first 2 hours of intravenous magnesium administration
|
Assessing ventricular rate control within the first 2 hours of intravenous magnesium administration as defined as a ventricular rate of < 120 bpm. |
Within the first 2 hours of intravenous magnesium administration
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to achieve goal HR (heart rate)
Tidsramme: 2 hours
|
Mean change in heart rate and rhythm after the administration of magnesium sulfate as well as after the administration of diltiazem |
2 hours
|
|
Rate of conversion
Tidsramme: 2 hours after administration of magnesium
|
Rate of conversion to normal sinus rhythm (NSR) |
2 hours after administration of magnesium
|
|
Incidence of hypotension
Tidsramme: At 1 and 2 hours after magnesium administration
|
SBP < 90 mmHg or MAP (mean arterial pressure) < 65 |
At 1 and 2 hours after magnesium administration
|
|
Change in heart rate
Tidsramme: up to 24 hours after magnesium infusion
|
Mean change in heart rate up to 24 hours after magnesium infusion |
up to 24 hours after magnesium infusion
|
|
Clinical need for rescue medication administration
Tidsramme: 2 hours from diltiazem administration
|
Dose and route of rescue medications given (magnesium and diltiazem) |
2 hours from diltiazem administration
|
|
Adverse effects
Tidsramme: 2 hours from diltiazem administration
|
Patient reported adverse effects (e.g.. flushing, headache, nausea, new onset or worsening lightheadedness since beginning the magnesium infusion) |
2 hours from diltiazem administration
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Travis Hase, MD, Wake Forest University Health Sciences
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Kardiovaskulære sykdommer
- Patologiske prosesser
- Hjertesykdommer
- Arytmier, hjerte
- Patologiske tilstander, tegn og symptomer
- Atrieflimmer
- Svovelforbindelser
- Uorganiske kjemikalier
- Klorforbindelser
- Svovelsyrer
- Natriumforbindelser
- Sulfater
- Svovelsyrer
- Klorider
- Saltsyre
- Magnesiumforbindelser
- Magnesiumsulfat
- Natriumklorid
Andre studie-ID-numre
- IRB00110863
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .